These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 9609749

  • 1. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
    Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR.
    Gastroenterology; 1998 Jun; 114(6):1133-42. PubMed ID: 9609749
    [Abstract] [Full Text] [Related]

  • 2. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
    Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR, ISIS 2302-CS9 Investigators.
    Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
    [Abstract] [Full Text] [Related]

  • 3. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
    Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G, German ICAM-1 Study Group.
    Gastroenterology; 2001 May; 120(6):1339-46. PubMed ID: 11313303
    [Abstract] [Full Text] [Related]

  • 4. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
    Maksymowych WP, Blackburn WD, Tami JA, Shanahan WR.
    J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
    [Abstract] [Full Text] [Related]

  • 5. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
    Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
    [Abstract] [Full Text] [Related]

  • 6. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.
    Yacyshyn BR, Schievella A, Sewell KL, Tami JA.
    Clin Exp Immunol; 2005 Jul; 141(1):141-7. PubMed ID: 15958080
    [Abstract] [Full Text] [Related]

  • 7. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
    Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR.
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1173-80. PubMed ID: 9316823
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
    Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E.
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
    [Abstract] [Full Text] [Related]

  • 11. Crohn's trial shows the pros of antisense.
    Robertson D.
    Nat Biotechnol; 1997 Mar; 15(3):209. PubMed ID: 9062911
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimens.
    Yu RZ, Su JQ, Grundy JS, Geary RS, Sewell KL, Dorr A, Levin AA.
    Antisense Nucleic Acid Drug Dev; 2003 Feb; 13(1):57-66. PubMed ID: 12691536
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Drug treatment for Crohn's disease.
    Yacyshyn BR.
    Lancet; 1998 Aug 29; 352(9129):743. PubMed ID: 9729027
    [No Abstract] [Full Text] [Related]

  • 16. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT, Sitaraman S.
    Curr Opin Investig Drugs; 2001 Oct 29; 2(10):1401-6. PubMed ID: 11890355
    [Abstract] [Full Text] [Related]

  • 17. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.
    Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando A, Pallone F.
    N Engl J Med; 2015 Mar 19; 372(12):1104-13. PubMed ID: 25785968
    [Abstract] [Full Text] [Related]

  • 18. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice.
    Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, Jacoby HI.
    J Pharmacol Exp Ther; 1997 Feb 19; 280(2):988-1000. PubMed ID: 9023316
    [Abstract] [Full Text] [Related]

  • 19. Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD.
    Philpott JR, Miner PB.
    Expert Opin Biol Ther; 2008 Oct 19; 8(10):1627-32. PubMed ID: 18774928
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.